Global News Wire: Novavax Initiating Human Clinical Trials for H7N9 Virus
Novavax, Inc (NVAX) is a clinical-stage biopharmaceutical company that strives to create novel vaccines to treat a broad spectrum of diseases around the world.
H7N9
News Medical: iBio Launch Platform Creates H7N9 Influenza Vaccine in Record Time
Influenza is a virus that is constantly changing and requires routine monitoring. Without the proper preparation, this advanced virus could develop in to a pandemic. IBio has produced a vaccine candidate for the newly emerging H7N9 influenza virus in a milestone time of 21 days.